BioServe, Beltsville, Md, has established a strategic alliance with DNAPrint Genomics Inc, Sarasota, Fla, to provide biomedical researchers with clinical DNA samples that will include genetic ancestry data for each sample.

With the added dimension of ancestry information in clinical samples, medical researchers should be able to determine if certain biological markers are artifacts of genetic ancestry, true markers for a disease, or a drug response in a disease.

To create the genetic ancestry data, DNAPrint Genomics will analyze and categorize BioServe’s global repository of nearly 600,000 human biological samples using its AncestrybyDNA validated genetic ancestry test.

Both companies provide genotyping services. The pairing makes the following platforms available: Beckman ultra high throughput SNP platform, Illumina SNP Golden Gate, and Sequenom iPLEX. Several gene RNA expression analysis platforms are available, including differential expression pattern display technology.
DNAPrint Genomics develops genomics-based products and services in two primary markets, biomedical and forensics. DNAPrint Pharmaceuticals Inc, a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the company’s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational biology and pharmacogenomics services are also offered externally to biopharmaceutical companies.

BioServe processes, develops, and validates diagnostic tests for the practice of personalized, predictive, and preventive medicine. Pharmaceutical, biotech, and diagnostic firms collaborate with the company to identify and validate markers that cause disease, while correlating clinical and molecular data to develop new diagnostic tests promoting wellness worldwide. BioServe’s global repository is a growing library of more than 600,000 human DNA, tissue, and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients hailing from four continents.